/ /

  • linkedin
  • Increase Font
  • Sharebar

    New pink eye treatment gets FDA nod


    A new type of ophthalmic fluoroquinolone has been approved by the Food and Drug Administration (FDA) for treatment of conjunctivitis, better known as pink eye.

    The drug, besifloxacin ophthalmic suspension (Besivance), is made by Bausch & Lomb. It was approved after FDA reviewed eight clinical trials of almost 2,400 patients. It’s indicated for topical ophthalmic use for those one year and older, for treating one of 13 bacteria strains, including Staphylococcus aureus, Streptococcus pneumonaie, and H influenza.


    Latest Tweets Follow